TNBC RNA subtyping compares gene-expression patterns under a named research classifier. Tissue mixture, method and version matter, and the result is separate from receptor tests or a treatment choice.
Lehmann's original TNBCtype system described six expression groups: BL1, BL2, IM, M, MSL and LAR. The 2016 TNBCtype-4 refinement retained BL1, BL2, M and LAR as tumour-focused profiles after evaluating immune and stromal contributions to the IM and MSL signals. Removed-profile samples were reassigned to their second-highest correlated tumour-profile centroid, not automatically to M.
BL1 is associated with cell-cycle/DNA-damage-response programmes; BL2 with growth-factor and myoepithelial-associated expression; M with motility and differentiation; and LAR with luminal and androgen-related transcription. These are classifier associations, not proof of one cause, functional repair deficiency or dependence on an inhibitor.
Evidence that a particular subtype-linked treatment strategy can be tested prospectively. Keep the classifier, genomic rules, population, comparator, endpoint and harms attached to the result.
Pooled evidence from 306 patients, building on an earlier report by Masuda and colleagues, that molecular subtype predicts chemotherapy response in triple-negative disease, and the origin of the observation that the immune signal in these tumours is real and measurable, which tumour-infiltrating lymphocyte scoring later turned into a prognostic tool.
The vocabulary used on the triple-negative page (basal-like 1 and 2, mesenchymal, luminal androgen receptor, immunomodulatory) comes from this paper; it made triple-negative breast cancer several diseases with several possible drugs rather than one disease with none.
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares Triple-negative breast cancer (TNBC) and the tag classification.
Shares Triple-negative breast cancer (TNBC) and the tag classification.
Shares Basal-like breast cancer, Triple-negative breast cancer (TNBC).
Shares Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Triple-negative breast cancer (TNBC).
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/